Moderna Inc. MRNA stock,
The company said on Monday that it plans to use its mRNA technology to start a new development program that will focus on developing vaccines against seasonal influenza, HIV and Nipah virus. This is another success following the success of its mRNA COVID-19 vaccine, which is one of two vaccines approved in the United States so far. CEOModerna also said that it plans to expand its respiratory syncytial virus to include the elderly, and plans to test different combinations of vaccines against influenza, COVID-1
9, RSV and human interstitial pneumonia virus. CEO Stephen Bancel (Stéphane Bancel) said in a press release: “For the entire society, 2020 is a challenging year. This is an extraordinary proof-of-concept period for Moderna.” As a corporate update In part, Moderna stated that as of December 31, it had approximately $5.2 billion in cash, compared with $1.2 billion in cash in the same period a year ago, and it expects to generate at least $11.7 billion in revenue based on the pre-purchase agreement for the COVID-19 vaccine It will be listed in 2021. Last year, Moderna’s stock rose by 489.1%, and the S&P 500 SPX,
It was up 19.7%.